Logo image of BILI

BILIBILI INC-SPONSORED ADR (BILI) Stock Fundamental Analysis

NASDAQ:BILI - Nasdaq - US0900401060 - ADR - Currency: USD

16.21  +0.02 (+0.12%)

After market: 16.29 +0.08 (+0.49%)

Fundamental Rating

3

Overall BILI gets a fundamental rating of 3 out of 10. We evaluated BILI against 70 industry peers in the Interactive Media & Services industry. Both the profitability and financial health of BILI have multiple concerns. BILI is growing strongly while it is still valued neutral. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

BILI had positive earnings in the past year.
BILI had negative earnings in each of the past 5 years.
In multiple years BILI reported negative operating cash flow during the last 5 years.
BILI Yearly Net Income VS EBIT VS OCF VS FCFBILI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2B -4B -6B

1.2 Ratios

BILI's Return On Assets of -4.12% is in line compared to the rest of the industry. BILI outperforms 51.43% of its industry peers.
BILI has a Return On Equity (-9.55%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -4.12%
ROE -9.55%
ROIC N/A
ROA(3y)-12.19%
ROA(5y)-12.45%
ROE(3y)-30.75%
ROE(5y)-32.63%
ROIC(3y)N/A
ROIC(5y)N/A
BILI Yearly ROA, ROE, ROICBILI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

With a Gross Margin value of 32.70%, BILI is not doing good in the industry: 74.29% of the companies in the same industry are doing better.
In the last couple of years the Gross Margin of BILI has grown nicely.
The Profit Margin and Operating Margin are not available for BILI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 32.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.17%
GM growth 5Y13.25%
BILI Yearly Profit, Operating, Gross MarginsBILI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

2

2. Health

2.1 Basic Checks

BILI does not have a ROIC to compare to the WACC, probably because it is not profitable.
BILI has more shares outstanding than it did 1 year ago.
The number of shares outstanding for BILI has been increased compared to 5 years ago.
BILI has a better debt/assets ratio than last year.
BILI Yearly Shares OutstandingBILI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
BILI Yearly Total Debt VS Total AssetsBILI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B 50B

2.2 Solvency

A Debt/Equity ratio of 0.34 indicates that BILI is not too dependend on debt financing.
BILI has a Debt to Equity ratio of 0.34. This is comparable to the rest of the industry: BILI outperforms 45.71% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Altman-Z N/A
ROIC/WACCN/A
WACC6.98%
BILI Yearly LT Debt VS Equity VS FCFBILI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B -5B 10B 15B 20B

2.3 Liquidity

BILI has a Current Ratio of 1.34. This is a normal value and indicates that BILI is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of BILI (1.34) is worse than 64.29% of its industry peers.
A Quick Ratio of 1.34 indicates that BILI should not have too much problems paying its short term obligations.
BILI has a worse Quick ratio (1.34) than 64.29% of its industry peers.
Industry RankSector Rank
Current Ratio 1.34
Quick Ratio 1.34
BILI Yearly Current Assets VS Current LiabilitesBILI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

More info and screens

7

3. Growth

3.1 Past

BILI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 130.35%, which is quite impressive.
BILI shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.10%.
The Revenue has been growing by 31.68% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)130.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%202.72%
Revenue 1Y (TTM)19.1%
Revenue growth 3Y11.45%
Revenue growth 5Y31.68%
Sales Q2Q%37.8%

3.2 Future

Based on estimates for the next years, BILI will show a very strong growth in Earnings Per Share. The EPS will grow by 210.16% on average per year.
The Revenue is expected to grow by 11.96% on average over the next years. This is quite good.
EPS Next Y6979.73%
EPS Next 2Y945.03%
EPS Next 3Y419.94%
EPS Next 5Y210.17%
Revenue Next Year13.49%
Revenue Next 2Y11.2%
Revenue Next 3Y10.24%
Revenue Next 5Y11.96%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
BILI Yearly Revenue VS EstimatesBILI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 10B 20B 30B 40B 50B
BILI Yearly EPS VS EstimatesBILI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 -10 20 30

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 57.89, which means the current valuation is very expensive for BILI.
The rest of the industry has a similar Price/Earnings ratio as BILI.
BILI's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 28.29.
Based on the Price/Forward Earnings ratio of 15.76, the valuation of BILI can be described as correct.
BILI's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. BILI is cheaper than 62.86% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.08, BILI is valued a bit cheaper.
Industry RankSector Rank
PE 57.89
Fwd PE 15.76
BILI Price Earnings VS Forward Price EarningsBILI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BILI Per share dataBILI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

BILI's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as BILI's earnings are expected to grow with 419.94% in the coming years.
PEG (NY)0.01
PEG (5Y)N/A
EPS Next 2Y945.03%
EPS Next 3Y419.94%

More info and screens

0

5. Dividend

5.1 Amount

BILI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BILIBILI INC-SPONSORED ADR

NASDAQ:BILI (4/17/2025, 8:04:03 PM)

After market: 16.29 +0.08 (+0.49%)

16.21

+0.02 (+0.12%)

Chartmill FA Rating
GICS SectorCommunication Services
GICS IndustryGroupMedia & Entertainment
GICS IndustryInteractive Media & Services
Earnings (Last)02-20 2025-02-20/bmo
Earnings (Next)N/A N/A
Inst Owners18.19%
Inst Owner Change0%
Ins Owners0.01%
Ins Owner ChangeN/A
Market Cap6.70B
Analysts81.62
Price Target25.8 (59.16%)
Short Float %6.66%
Short Ratio3.01
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.01%
Min EPS beat(2)-7.94%
Max EPS beat(2)9.96%
EPS beat(4)3
Avg EPS beat(4)7.41%
Min EPS beat(4)-7.94%
Max EPS beat(4)14.41%
EPS beat(8)6
Avg EPS beat(8)7.47%
EPS beat(12)9
Avg EPS beat(12)5.31%
EPS beat(16)13
Avg EPS beat(16)7.06%
Revenue beat(2)1
Avg Revenue beat(2)-0.15%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)0.42%
Revenue beat(4)1
Avg Revenue beat(4)-0.84%
Min Revenue beat(4)-1.54%
Max Revenue beat(4)0.42%
Revenue beat(8)1
Avg Revenue beat(8)-1.47%
Revenue beat(12)1
Avg Revenue beat(12)-1.55%
Revenue beat(16)3
Avg Revenue beat(16)-1.09%
PT rev (1m)3.48%
PT rev (3m)9.96%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-41.72%
EPS NY rev (1m)2.51%
EPS NY rev (3m)-0.2%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.75%
Revenue NY rev (1m)-0.07%
Revenue NY rev (3m)0.1%
Valuation
Industry RankSector Rank
PE 57.89
Fwd PE 15.76
P/S 1.82
P/FCF N/A
P/OCF N/A
P/B 3.47
P/tB 5.98
EV/EBITDA N/A
EPS(TTM)0.28
EY1.73%
EPS(NY)1.03
Fwd EY6.34%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS8.89
BVpS4.68
TBVpS2.71
PEG (NY)0.01
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.12%
ROE -9.55%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 32.7%
FCFM N/A
ROA(3y)-12.19%
ROA(5y)-12.45%
ROE(3y)-30.75%
ROE(5y)-32.63%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.17%
GM growth 5Y13.25%
F-ScoreN/A
Asset Turnover0.82
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.34
Quick Ratio 1.34
Altman-Z N/A
F-ScoreN/A
WACC6.98%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)130.35%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%202.72%
EPS Next Y6979.73%
EPS Next 2Y945.03%
EPS Next 3Y419.94%
EPS Next 5Y210.17%
Revenue 1Y (TTM)19.1%
Revenue growth 3Y11.45%
Revenue growth 5Y31.68%
Sales Q2Q%37.8%
Revenue Next Year13.49%
Revenue Next 2Y11.2%
Revenue Next 3Y10.24%
Revenue Next 5Y11.96%
EBIT growth 1Y73.46%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year392.03%
EBIT Next 3Y85.33%
EBIT Next 5Y52.4%
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A